15 results
6-K
EX-99.1
IMRN
Immuron Limited
28 Sep 23
Report of Foreign Private Issuer
8:43am
and delivers innovative biotherapies, Dr. Kanellos gained considerable experience in the international drug development process, formulation development
6-K
EX-99.1
IMRN
Immuron Limited
24 Jul 23
Immuron CEO, Steven Lydeamore to present at Bioshares
6:04am
, and optimize health and performance of U.S. military personnel and civilians Focuses on innovative medical solutions to a range of Force Health Protection
6-K
EX-99.1
cveu3el7ygjqnz3u9w6
23 Sep 21
Immuron planned Acquisition of R&D Vaccine Company
7:13am
424B5
r849e
17 Jul 19
Prospectus supplement for primary offering
4:20pm
424B5
o9ffx9 u7nh
16 Jul 19
Prospectus supplement for primary offering
5:25pm
424B5
wrr4y6
28 May 19
Prospectus supplement for primary offering
12:00am
424B5
5h56318900a4op5zg
23 May 19
Prospectus supplement for primary offering
4:07pm
POS AM
a0opxzo
14 Jan 19
Prospectus update (post-effective amendment)
12:01pm
20-F
v5gsf4v10uolz nbj
2 Nov 17
Annual report (foreign)
12:00am
- Prev
- 1
- Next